Natural History Study of Patients With Excess Androgen
Key facts
- Who runs it
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Where
- Bethesda and Washington D.C., United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 2 Jan 2006
- Type of study
- Observational, 5 groups
- Record updated
- 12 November 2026
Who can take part
- Age
- 1 day to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who cannot take part
- Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a patient is determined to have PCOS as the only cause of her hyperandrogenism; she will no longer be followed on this protocol
- Patients with significant non-endocrine medical conditions
- Females who are pregnant at the time of initial enrollment
Other criteria
- INCLUSION CRITERIA:; Males, ages 0 - 99 with known or suspected FMPP or; Patients (males and females, ages 0 - 99) with known or suspected (based on hormonal, clinical and/or genetic testing) CAH of any type; Patients with excess androgen of unknown etiology or; Relatives of patients in this protocol
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: NIH Clinical Center Office of Patient Recruitment (OPR)Taking people
- MedStar Washington Hospital CenterWashington D.C., United StatesContact: Deborah P Merke, M.D.No longer taking part
About the trial
What the trial wants to find out
This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and early puberty with early cessation of growth and short stature in adulthood. Too much androgen in adulthood may result in infertility, and women may have excess facial hair, acne and a more male-like appearance. Excess androgen may also affect mood and behavior and possibly the secretion of other hormones, such as insulin. Two genetic diseases that result in early childhood androgen excess are congenital adrenal hyperplasia (CAH) and familial male-limited precocious puberty (FMPP).
Read full original descriptionShow less
Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH are eligible, and patients with androgen excess of unknown cause may be eligible.
Participants undergo the following procedures:
* Medical history and physical examination. * Fasting blood tests for analysis of hormones, blood chemistries including blood sugar and cardiovascular risk factors such as lipids. * Oral glucose tolerance test for patients with elevated insulin levels. For this test, a catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a sugar-containing fluid and blood samples are collected through the catheter at intervals starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the solution. * 24-hour urine collection to measure hormone levels in the urine. * DNA testing for patients with 21-hydroxylase deficiency to help identify the type of genetic mutation responsible for the disease. * X-ray of the left hand to measure bone age in growing children. The x-ray is used to determine how far into puberty the child is and how much growth potential is left in the bones. * A pelvic ultrasound in females and testicular ultrasound in males to evaluate the size and development of the gonads (ovaries in females and testes in males). * Cognitive and psychological tests, including an IQ test and evaluation of memory, achievement and behavior. * Other tests and evaluations based on medical need.
The schedule for these procedures varies. In a part of the study involving only patients with CAH, growing children are evaluated twice (once in childhood and once after reaching adult height), and adults are evaluated once. In another part of the study involving patients with CAH and FMPP, growing children are seen twice a year, and adults and children who have reached adult height may be seen annually. Additional visits may be scheduled if medically indicated. In this part of the study, females are asked to keep a record of their periods after their first menstrual cycle.
...
The 5 groups in the trial
- 1/CAH Patients Managed at the NIH
Patients with Congenital Adrenal Hyperplasia (CAH).
- 2/CAH Patients Managed by Outside Physicians
Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit at NIH.
- 3/Relatives of Patients
Relatives (mostly parents) of patients will be genotyped. This is often necessary to establish the genotype of the patient.
- 4/FMPP Patients
Patients with Familial Male-Limited Precocious Puberty (FMPP).
- 5/Patients with Androgen Excess of Unknown Etiology
Patients with Androgen Excess of Unknown Etiology followed by home physician post visit at NIH.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Course of COVID-19 infection in patients with congenital adrenal hyperplasia.Frontiers in endocrinology, 2024
- Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X.Genes, 2023
- Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia.The Journal of clinical endocrinology and metabolism, 2021
- Complement component 4 variations may influence psychopathology risk in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Human genetics, 2018
- 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal Rest Tumors in 21-Hydroxylase Deficiency.The Journal of clinical endocrinology and metabolism, 2017
- Record updated
- 12 November 2026